<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Muecksch F</submitter><funding>NIAID NIH HHS</funding><pubmed_abstract>&lt;h4>Background&lt;/h4>Serological assays are being deployed to monitor antibody responses in SARS-CoV-2 convalescents and vaccine recipients. There is a need to determine whether such assays can predict immunity, as antibody levels wane and viral variants emerge.&lt;h4>Methods&lt;/h4>We measured antibodies in a cohort of SARS-CoV-2 infected patients using several high-throughput serological tests and functional neutralization assays. The effects of time and spike protein sequence variation on the performance and predictive value of the various assays was assessed.&lt;h4>Findings&lt;/h4>Neutralizing antibody titers decreased over the first few months post-infection but stabilized thereafter, at about 30% of the level observed shortly after infection. Serological assays commonly used to measure antibodies </pubmed_abstract><journal>medRxiv : the preprint server for health sciences</journal><pagination>2021.07.02.21259939</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8282113</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity.</pubmed_title><pmcid>PMC8282113</pmcid><funding_grant_id>R01 AI078788</funding_grant_id><funding_grant_id>R01 AI050111</funding_grant_id><pubmed_authors>Malloy K</pubmed_authors><pubmed_authors>Zhang F</pubmed_authors><pubmed_authors>Bieniasz P</pubmed_authors><pubmed_authors>Hatziioannou T</pubmed_authors><pubmed_authors>Schmidt F</pubmed_authors><pubmed_authors>Jenks S</pubmed_authors><pubmed_authors>McCance K</pubmed_authors><pubmed_authors>Squires M</pubmed_authors><pubmed_authors>Mavin S</pubmed_authors><pubmed_authors>Templeton K</pubmed_authors><pubmed_authors>Muecksch F</pubmed_authors><pubmed_authors>Batchelor B</pubmed_authors><pubmed_authors>Richardson C</pubmed_authors><pubmed_authors>Burns A</pubmed_authors><pubmed_authors>Furrie E</pubmed_authors><pubmed_authors>Godber I</pubmed_authors><pubmed_authors>Jarvis L</pubmed_authors><pubmed_authors>MacGuire J</pubmed_authors><pubmed_authors>Wise H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity.</name><description>&lt;h4>Background&lt;/h4>Serological assays are being deployed to monitor antibody responses in SARS-CoV-2 convalescents and vaccine recipients. There is a need to determine whether such assays can predict immunity, as antibody levels wane and viral variants emerge.&lt;h4>Methods&lt;/h4>We measured antibodies in a cohort of SARS-CoV-2 infected patients using several high-throughput serological tests and functional neutralization assays. The effects of time and spike protein sequence variation on the performance and predictive value of the various assays was assessed.&lt;h4>Findings&lt;/h4>Neutralizing antibody titers decreased over the first few months post-infection but stabilized thereafter, at about 30% of the level observed shortly after infection. Serological assays commonly used to measure antibodies </description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Jul</publication><modification>2026-06-19T03:18:12.936Z</modification><creation>2022-02-11T16:05:15.757Z</creation></dates><accession>S-EPMC8282113</accession><cross_references><pubmed>34268524</pubmed><doi>10.1101/2021.07.02.21259939</doi></cross_references></HashMap>